+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Induced Pluripotent Stem Cell (iPSC) - Global Market Trajectory & Analytics

  • ID: 4805485
  • Report
  • May 2021
  • Region: Global
  • 349 pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Axol Bioscience Ltd.
  • Evotec SE
  • Fate Therapeutics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • MORE

Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $2.3 Billion by 2026


Induced pluripotent stem cells (iPSCs) hold tremendous clinical potential to transform the entire therapeutic landscape by offering treatments for various medical conditions and disorders. These cells are derived from somatic cells like blood or skin cells that are genetically reprogrammed into embryonic stem cell-like state for developing an unlimited source of a diverse range of human cells for therapeutic applications. The global market is propelled by increasing demand for these cells, rising focus on researchers in the field, and their potential application in treatment of various diseases. The market growth is supplemented by rising prevalence of several chronic disorders such as diabetes, heart disease, stroke and cancer. Moreover, increasing awareness about stem cells and associated research, potential clinical applications and rising financial assistance by governments and private players are expected to contribute significantly to the market expansion. The iPSC technique is anticipated to find extensive adoption in the pharmaceutical industry for developing efficient cell sources like iPSC-derived functional cells to support drug screening and toxicity testing.

Amid the COVID-19 crisis, the global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2026, growing at a CAGR of 6.6% over the analysis period. Vascular Cells, one of the segments analyzed in the report, is projected to record a 7.2% CAGR and reach US$835.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiac Cells segment is readjusted to a revised 7.9% CAGR for the next 7-year period. The demand for iPSC-derived cardiac cells is attributed to diverse applications including cardiotoxicity testing, drug screening and drug validation along with metabolism studies and electrophysiology applications.

The U.S. Market is Estimated at $767.1 Million in 2021, While China is Forecast to Reach $82.4 Million by 2026


The Induced Pluripotent Stem Cell ((iPSC) market in the U.S. is estimated at US$767.1 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$82.4 Million by the year 2026 trailing a CAGR of 8.5% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5 % and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR. North America leads the global market, supported by continuing advances related to iPSC technology and access to functional cells used in pre-clinical drug screening. The market growth is supplemented by increasing insights into the iPSC platform along with high throughput analysis for drug toxicity. The iPSC market in Asia-Pacific is estimated to post a fast growth due to increasing R&D projects across countries like Australia, Japan and Singapore.

Neuronal Cells Segment to Reach $336.9 Million by 2026


In the global Neuronal Cells segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$202.9 Million in the year 2020 will reach a projected size of US$308 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.8 Million by the year 2026.

Select Competitors (Total 51 Featured) -

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Axol Bioscience Ltd.
  • Evotec SE
  • Fate Therapeutics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • MORE
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Induced Pluripotent Stem Cells (iPSCs) Market Gains from Increasing Use in Research for COVID-19
  • Studies Employing iPSCs in COVID-19 Research
  • Stem Cells, Application Areas, and the Different Types: A Prelude
  • Applications of Stem Cells
  • Types of Stem Cells
  • Induced Pluripotent Stem Cell (iPSC): An Introduction
  • Production of iPSCs
  • First & Second Generation Mouse iPSCs
  • Human iPSCs
  • Key Properties of iPSCs
  • Transcription Factors Involved in Generation of iPSCs
  • Noteworthy Research & Application Areas for iPSCs
  • Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects and Outlook
  • Drug Development Application to Witness Considerable Growth
  • Technical Breakthroughs, Advances & Clinical Trials to Spur Growth of iPSC Market
  • North America Dominates Global iPSC Market
  • Competition
  • Recent Market Activity
  • Select Innovation/Advancement
  • Axol Bioscience Ltd. (UK)
  • Cynata Therapeutics Limited (Australia)
  • Evotec SE (Germany)
  • Fate Therapeutics, Inc. (USA)
  • FUJIFILM Cellular Dynamics, Inc. (USA)
  • Ncardia (Belgium)
  • Pluricell Biotech (Brazil)
  • REPROCELL USA, Inc. (USA)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Takara Bio, Inc. (Japan)
  • Thermo Fisher Scientific, Inc. (USA)
  • ViaCyte, Inc. (USA)
  • Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments
  • Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
  • Research Trends in Induced Pluripotent Stem Cell Space
  • Exhibit 1: Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016
  • Exhibit 2: Number of Original Research Papers on hESC and iPSC Published Worldwide (2014-2016)
  • Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
  • Regenerative Medicine: A Promising Application of iPSCs
  • Induced Pluripotent: A Potential Competitor to hESCs?
  • Exhibit 3: Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
  • Exhibit 4: Global Stem Cell & Regenerative Medicine Market by Product (in %) for the Year 2019
  • Exhibit 5: Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019
  • Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
  • Exhibit 6: Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017
  • Exhibit 7: Leading Causes of Mortality for Low-Income and High-Income Countries
  • Growing Importance of iPSCs in Personalized Drug Discovery
  • Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
  • Exhibit 8: Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
  • Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
  • Exhibit 9: Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
  • Exhibit 10: Number of New Cancer Cases Reported (in Thousands) by Cancer Type: 2018
  • Exhibit 11: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Exhibit 12: Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
  • Exhibit 13: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Growth in Number of Genomics Projects Propels Market Growth
  • Exhibit 14: Genomic Initiatives in Select Countries
  • Exhibit 15: New Gene-Editing Tools Spur Interest and Investments in Genetics, Driving Lucrative Growth Opportunities for iPSCs: Total VC Funding (In US$ Million) in Genetics for the Years 2014, 2015, 2016, 2017 and 2018
  • Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit Market Growth
  • Exhibit 16: Number of Induced Pluripotent Stem Cells based Studies by Select Condition: As on Oct 31, 2020
  • iPSCs-based Clinical Trial for Heart Diseases
  • Induced Pluripotent Stem Cells for Stroke Treatment
  • ‘Off-the-shelf’ Stem Cell Treatment for Cancer Enters Clinical Trial
  • iPSCs for Hematological Disorders
  • Market Benefits from Growing Funding for iPSCs-Related R&D Initiatives
  • Exhibit 17: Stem Cell Research Funding in the US (in US$ Million) for the Years 2016 through 2021
  • Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
  • Exhibit 18: Human iPSC Banks Worldwide: An Overview
  • Exhibit 19: Cell Sources and Reprogramming Methods Used by Select iPSC Banks
  • Innovations, Research Studies & Advancements in iPSCs
  • Key iPSC Research Breakthroughs for Regenerative Medicine
  • Researchers Develop Novel Oncogene-Free and Virus-Free iPSC Production Method
  • Scientists Study Concerns of Genetic Mutations in iPSCs
  • iPSCs Hold Tremendous Potential in Transforming Research Efforts
  • Researchers Highlight Potential Use of iPSCs for Developing Novel Cancer Vaccines
  • Scientists Use Machine Learning to Improve Reliability of iPSC Self-Organization
  • STEMCELL Technologies Unveils mTeSR™ Plus
  • Challenges and Risks Related to Pluripotent Stem Cells
  • A Glance at Issues Related to Reprogramming of Adult Cells to iPSCs
  • A Note on Legal, Social and Ethical Considerations with iPSCs
III. MARKET ANALYSIS

IV. COMPETITION
  • Total Companies Profiled: 51
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • Pluricell Biotech
  • REPROCELL USA, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll